ABSTRACT
Objective: The psychological morbidities following coronavirus disease (COVID-19) infection among survivors have been identified as a significant public health challenge since the beginning of the COVID-19 pandemic. Emerging evidence indicates higher prevalence of psychological consequences among elderly COVID-19 survivors. The aim of this study was to explore the psychological morbidities among elderly COV-ID-19 survivors and associated socio-demographic and clinical factors. Methods: A cross-sectional study among older COVID-19 survivors (age >50 years) was conducted in a tertiary care hospital from October 2021 to December 2021. Patients attending medical outpatient department were screened for laboratory-confirmed COVID-19 infection in the past and they were recruited for the study after obtaining written informed consent. The study used a semi-structured proforma and rating scales such as Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder Scale (GAD-7), and The Insomnia Severity Index (ISI) for depression, anxiety, and insomnia, respectively. Results: The study results indicate that the prevalence of depression, anxiety, and insomnia among 99 older COVID-19 survivors is 35.4%, 31.3%, and 21.2%, respectively. There was statistically significant higher mean of ISI total score (p=0.012) among females. There was statistically significant higher mean PHQ-9 total score among widowed/seperated/divorced group when compared to married group (p=0.006). There was statistically significant higher mean ISI total score (p=0.011) among patients who received oxygen therapy while admitted for COVID-19. There was significantly higher rate of depression among females (p=0.047), widowed/seperated/divorced group (p=0.001), and patients who received oxygen therapy (p=0.004). Conclusion: This study findings implicates that elderly COVID-19 survivors are at significantly higher risk for post-COVID-19 psychological morbidities and should be screened regularly during follow-ups for timely and effective management. Copyright © 2022 Korean Academy of Sleep Medicine
ABSTRACT
Although the coronavirus disease (COVID-19) in the pediatric population appears to be less severe among children <18 years old, emerging evidence from Europe, North America, Asia, and Latin America indicates that COVID-19 infection may precipitate the hyperinflammatory state among children following infection. This paper reports a case of multisystem inflammatory syndrome with features of incomplete Kawasaki disease in an adolescent boy who also tested positive for COVID-19 antibody. This case highlights the potential COVID-19 complications in adolescents. © 2021 Asociacion Espanola de Dietistas-Nutricionistas. All rights reserved.
ABSTRACT
Objective: Coronavirus disease (COVID-19) infection predisposes patients to various psychiatric disorders. Study results indicate significantly higher prevalence of insomnia among patients with COVID-19 during active phase. Acute insomnia during active phase of COVID-19 can persist even after recovery, and can transform into chronic insomnia. There are not many studies exploring insomnia among COVID-19 survivors. Our study aims to explore insomnia and its correlation among healthcare workers with confirmed infection of COVID-19 after recovery. Methods: One hundred and seven COVID-19 survivors participated in the study. The social demographic and clinical information of all participants was collected by a structured self report questionnaire. Insomnia was evaluated using the Insomnia Severity Index. Results: The prevalence of insomnia was 21.5% among the healthcare workers with confirmed COVID-19 infection after recovery. There were significant positive correlation between the duration of fever and insomnia severity (0.247, p=0.01). Conclusion: Our study among healthcare workers recovered from COVID-19 provides evidence for high prevalence of insomnia among COVID-19 survivors. The results of this study demands that specific support measures should be planned and implemented to address insomnia among healthcare workers recovered from COVID-19. © 2021 Korean Academy of Sleep Medicine.
ABSTRACT
An outbreak of a novel corona virus disease-19 (nCoV-19) infection began in December 2019 in Wuhan, China, and now involved in the whole word. Globally around 20 million peoples are been infected by novel corona virus. With its staggering world wide morbidity and mortality, the scientific community has been under extra ordinary pressure to find safe and effective treatment, pending the availability of a vaccine. Certain medications, for example, dexamethasone, antimalarials (chloroquine/hydroxychloroquine), antiviral (remdesivir), and IL-6 receptor blocking monoclonal antibodies (tocilizumab) are used in various combinations as off-label medications to treat COVID-19. Here we are discussing 5 cases of covid 19 with different treatment approaches, and analyze the clinical outcome and effectiveness of the drug towards Covid 19.